List view / Grid view
A combination of dexamethasone, remdesivir, and baricitinib was associated with a ‘significant survival benefit’ when compared with dual therapy of dexamethasone with remdesivir, according to a retrospective study.
A clinical trial in hospitalised COVID-19 patients has demonstrated that baricitinib and remdesivir reduce time to recovery.
A study of baricitinib in combination with remdesivir has met its primary endpoint in COVID-19 patients, by reducing time to recovery in comparison with only remdesivir.
Gilead Sciences has said it will initiate clinical trials in August to test an inhaled formulation of remdesivir, a potential COVID-19 therapy.